Neurocrine Biosciences
NBIX
NBIX
570 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2024 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 235 increasing their positions, 201 reducing their positions, and 84 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
4% less funds holding
Funds holding: 591 → 570 (-21)
17% less capital invested
Capital invested by funds: $12.9B → $10.7B (-$2.17B)
19% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 84
Holders
570
Holding in Top 10
10
Calls
$79.4M
Puts
$74M
Top Buyers
| 1 | +$118M | |
| 2 | +$72.1M | |
| 3 | +$71.4M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$62.2M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$41.9M |
Top Sellers
| 1 | -$99.6M | |
| 2 | -$91.8M | |
| 3 | -$74.5M | |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$68M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$66.7M |